Outcome and survival of myeloma patients diagnosed 2008

  • Slides: 8
Download presentation
Outcome and survival of myeloma patients diagnosed 2008 – 2015. Real-world data on 4904

Outcome and survival of myeloma patients diagnosed 2008 – 2015. Real-world data on 4904 patients from the Swedish Myeloma Registry by Cecilie Hveding Blimark, Ingemar Turesson, Anna Genell, Lucia Ahlberg, Bo Björkstrand, Kristina Carlson, Karin Forsberg, Gunnar Juliusson, Olle Linder, Ulf. Henrik Mellqvist, Hareth Nahi, Sigurdur Y. Kristinsson, and haematol Volume 103(3): 506 -513 February 28, 2018 © 2018 by Ferrata Storti Foundation

Characteristics of active myeloma (MM) and smoldering myeloma (SMM) patients in the Swedish Myeloma

Characteristics of active myeloma (MM) and smoldering myeloma (SMM) patients in the Swedish Myeloma Registry. Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Age distribution in the Swedish Myeloma Registry in men and women in (A) active

Age distribution in the Swedish Myeloma Registry in men and women in (A) active myeloma (MM) and (B) smoldering myeloma (SMM). n: number. Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Prevalence of myeloma-related organ and tissue impairment (ROTI) and International Staging System (ISS) stage

Prevalence of myeloma-related organ and tissue impairment (ROTI) and International Staging System (ISS) stage at diagnosis in patients with active myeloma at diagnosis in the Swedish Myeloma Registry. Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Proportion of patients who received novel drugs (thalidomide, bortezomib or lenalidomide) as first-line treatment

Proportion of patients who received novel drugs (thalidomide, bortezomib or lenalidomide) as first-line treatment among active myeloma patients with reported follow up, by year of diagnosis and by age group (− 65, 66– 80, >80) years in the Swedish Myelom. . . Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Proportion with very good partial remission (VGPR) or better among active myeloma patients with

Proportion with very good partial remission (VGPR) or better among active myeloma patients with reported follow up after first-line treatment in patients diagnosed 2008– 2014 in the Swedish Myeloma Registry, by year of diagnosis and by age group (− 65, 66– 80, . . . Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Survival in active myeloma (MM) in the Swedish Myeloma Registry: observed (A) and relative

Survival in active myeloma (MM) in the Swedish Myeloma Registry: observed (A) and relative (B) survival, by 10 -year age cohorts. n: number. Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Relative survival in active myeloma (MM) by treatment response in the Swedish Myeloma Registry

Relative survival in active myeloma (MM) by treatment response in the Swedish Myeloma Registry in age cohorts: (A) under 65 years of age and (B) 66 years of age and over. Cecilie Hveding Blimark et al. Haematologica 2018; 103: 506513 © 2018 by Ferrata Storti Foundation

Outcome and survival of myeloma patients diagnosed 2008Outcome and survival of myeloma patients diagnosed 2008
Survival of European patients diagnosed with myeloid malignanciesSurvival of European patients diagnosed with myeloid malignancies
Overall Survival of Patients with RelapsedRefractory Multiple MyelomaOverall Survival of Patients with RelapsedRefractory Multiple Myeloma
Multiple Myeloma Treatment Options for Newly Diagnosed TheMultiple Myeloma Treatment Options for Newly Diagnosed The
Second Primary Malignancies in Newly Diagnosed Multiple MyelomaSecond Primary Malignancies in Newly Diagnosed Multiple Myeloma
Safety of thalidomide in newly diagnosed elderly myelomaSafety of thalidomide in newly diagnosed elderly myeloma
Outcomes of newly diagnosed multiple myeloma with deferredOutcomes of newly diagnosed multiple myeloma with deferred